The American Association for Cancer Research (AACR) publishes 10 highly esteemed journals that cover the full spectrum of cancer science and medicine. Earlier this year, two of those journals announced new editors-in-chief. Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center was named editor-in-chief of Clinical Cancer Research, while Daniel K. Nomura, PhD, of the University of California, Berkeley, was named editor-in-chief of Molecular Cancer Therapeutics.

Additionally, more than 45 oral and poster presentations at the AACR Annual Meeting 2025 will be simultaneously published as articles in AACR journals, reflecting the high number of meritorious abstracts submitted for presentation at the meeting. Some of the studies are listed below, by day with session/presentation details, and will be concurrently published in the AACR journals noted. Direct links to the journal articles will be available here as they are published. 

---

Sunday, April 27

Oral Presentations

The influence of extrachromosomal DNA (ecDNA) in cancer

Session: PL02 – Opening Plenary: Unifying Cancer Science and Medicine—A Continuum of Innovation for Impact
Time: 9:30-11:30 a.m. CT
Location: Hall B1, McCormick Place North (Level 3)
Journal: Cancer Discovery

Addressing tumor heterogeneity: Personalized cancer vaccines

Session: PL02 – Opening Plenary: Unifying Cancer Science and Medicine—A Continuum of Innovation for Impact
Time: 9:30-11:30 a.m. CT
Location: Hall B1, McCormick Place North (Level 3)
Journal: Cancer Discovery

Illuminating and reprogramming the immuno-evasive tumor microenvironment to enable immunotherapy

Session: LE19 – Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research
Time: 12-12:45 p.m. CT
Location: Room S100 A (Grand Ballroom A), McCormick Place South (Level 1)
Journal: Cancer Discovery

Developmental dependency and metabolic vulnerabilities in NUP98-rearranged pediatric leukemia

Session: SY34 – Fusion Oncoprotein-driven Malignancies: From Mechanisms to Therapies
Time: 1-2:45 p.m. CT
Location: Room E450 B, McCormick Lakeside Center (Level 4)
Journal: Blood Cancer Discovery

Decoding tumor cell dynamics driven by mutant TP53 gain-of-function activity in squamous cell carcinoma metastasis

Session: LBMS01 – Minisymposium: Late-Breaking Research
Time: 3-4:45 p.m. CT
Location: Room S403, McCormick Place South (Level 4)
Journal: Cancer Discovery

Poster Presentations

Exploring STEAP1 expression in prostate cancer cells in response to androgen deprivation and in small extracellular vesicles

Session: PO.ET06.04 – Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes
Time: 2-5 p.m. CT
Location: Poster Section 22, Poster Board Number: 14
Journal: Molecular Cancer Research

Targeting NOS sensitizes the NRAS-mutant melanomas to MEK inhibition and induces immunogenic cell death

Session: PO.MCB03.03 – Growth Factors, Receptors, and GTPase Signaling
Time: 2-5 p.m. CT
Location: Poster Section 10, Poster Board Number: 3
Journal: Cancer Research

Incidence of depression and anxiety in kidney cancer survivors: A nationwide population-based cohort study

Session: PO.CL12.01 – Survivorship Research and Supportive Care
Time: 2-5 p.m. CT
Location: Poster Section 33, Poster Board Number: 15
Journal: Cancer Epidemiology, Biomarkers & Prevention

---

Monday, April 28

Oral Presentations

Targeting Resistance to RAS inhibition in pancreatic cancer

Session: AOS09 – Advances in KRAS Biology Are Providing New Therapeutic Opportunities For Pancreatic Cancer
Time: 10:15-11:45 a.m. CT
Location: Room S100 A (Grand Ballroom A), McCormick Place South (Level 1)
Journal: Cancer Discovery

The spatial organization of lymphoma cells with MYC-BCL2 co-expression shapes the immune microenvironment and determines survival after chemoimmunotherapy

Session: AHM03 – Dissecting and Engaging the Lymphoma Tumor Microenvironment
Time: 12:30-2 p.m. CT
Location: Room S401, McCormick Place South (Level 4)
Journal: Blood Cancer Discovery

Mechanism of response and resistance to ​RAS inhibition in solid tumors

Session: SY08 – Developments in RAS Signaling Inhibition: Bench to Bedside
Time: 12:30-2 p.m. CT
Location: Room S100 A (Grand Ballroom A), McCormick Place South (Level 1)
Journal: Cancer Discovery

Reprogramming the tumor microenvironment with a single punch—our journey from bench to bedside

Session: SY21 – Immunometabolism and Metabolic Fitness in Tumors
Time: 12:30-2 p.m. CT
Location: Room S105, McCormick Place South (Level 1)
Journal: Cancer Discovery

Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in AML

Session: MS.MD01.04 – Cutting-Edge Advances in Hematology: CAR-T Therapy, B-cell Transformation, Leukemia Mechanisms, and Targeted Drug Development
Time: 2:30-4:30 p.m. CT
Location: Room S402, McCormick Place South (Level 4)
Journal: Blood Cancer Discovery

Poster Presentations

Predictive effect of IGFBP-3 on low-dose tamoxifen efficacy in non-invasive breast cancer in the phase III Tam-01 trial

Session: PO.PR01.05 – Biology of Precancers, Development of Early Detection Methods and Biomarkers, and Cancer Interception
Time: 9 a.m. to 12 p.m. CT
Location: Poster Section 42, Poster Board Number: 4
Journal: Clinical Cancer Research

Prognostic value of CD8+ T-cells at the invasive margin is comparable to immune score in non-metastatic colorectal cancer: A prospective multicentric cohort study

Session: PO.BCS02.01 – Digital Pathology
Time: 9 a.m. to 12 p.m. CT
Location: Poster Section 46, Poster Board Number: 9
Journal: Clinical Cancer Research

Inhibition of the tumor cell TCA cycle suppresses ER stress-associated THBS2 to selectively potentiate antitumor response of CD36+ effector T cells

Session: PO.IM01.02 – Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression
Time: 9 a.m. to 12 p.m. CT
Location: Poster Section 38, Poster Board Number: 13
Journal: Cancer Research

Navitoclax, a Bcl-2/xL inhibitor, and YM155, a survivin inhibitor, in combination with carboplatin effectively inhibit ovarian cancer tumor growth

Session: PO.ET02.03 – Drug Combination Strategies for Cancer Treatment
Time: 9 a.m. to 12 p.m. CT
Location: Poster Section 19, Poster Board Number: 8
Journal: Molecular Cancer Therapeutics

Mapping drug-gene interactions in cancer with large language models

Session: PO.BCS01.02 – Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery
Time: 2-5 p.m. CT
Location: Poster Section 45, Poster Board Number: 2
Journal: Cancer Research Communications

Socio-environmental exposure leads to disparities in colorectal cancer mortality and tumor biology in metropolitan Detroit

Session: PO.PS01.03 – Cancer Disparities: Environmental, Microbiome, and Tumor Biology
Time: 2-5 p.m. CT
Location: Poster Section 43, Poster Board Number: 1
Journal: Cancer Research Communications

---

Tuesday, April 29

Oral Presentations

Metastatic dissemination from the perspective of the cancer cell, its microenvironment, and the host

Session: PL04 – Targeting the Cancer Ecosystem
Time: 8-10 a.m. CT
Location: Hall B1, McCormick Place North (Level 3)
Journal: Cancer Discovery

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection

Session: AED02 – Opportunities in Cancer Early Detection Using Next Generation Liquid Biopsies
Time: 10:15-11:45 a.m. CT
Location: Room S100 BC (Grand Ballroom BC), McCormick Place South (Level 1)
Journal: Cancer Discovery

Advances in ctDNA MRD analysis for early-stage cancers

Session: SY10 – Technical and Clinical Advances in Circulating Tumor DNA Minimal Residual Disease Detection
Time: 12:30-2:30 p.m. CT
Location: Arie Crown Theater, McCormick Lakeside Center (Level 2)
Journal: Cancer Discovery

Perivascular niche-resident alveolar macrophages confer interstitial pneumonitis related to trastuzumab deruxtecan

Session: MS.CL08.01 – Targeted Therapies and Combinations
Time: 2:30-4:15 p.m. CT
Location: Room E451, McCormick Lakeside Center (Level 4)
Journal: Cancer Research

Preclinical efficacy of combinatorial B7-H3 CAR T cell and ONC206 treatment in DIPG/DMG

Session: MS.IM01.01 – Adoptive Cell Therapies
Time: 2:30-4 p.m. CT
Location: Arie Crown Theater, McCormick Lakeside Center (Level 2)
Journal: Cancer Discovery

Curing aggressive lymphomas using multi-drug combinations targeting oncogenic survival pathways

Session: LE05 – AACR Award for Outstanding Achievement in Blood Cancer Research
Time: 4:30-5:15 p.m. CT
Location:  Room S105, McCormick Place South (Level 1)
Journal: Blood Cancer Discovery

Poster Presentations

Lung cancer autochthonous model gene expression database

Session: PO.TB04.01 – Mouse and Other Models
Time: 9 a.m. to 12 p.m. CT
Location: Poster Section 4, Poster Board Number: 16
Journal: Cancer Research

Neoadjuvant durvalumab and olaparib in resectable urothelial bladder cancer—Impact on its molecular profile and efficacy: Neodurvarib trial

Session: PO.CT02.01 – Phase II Clinical Trials 1
Time: 9 a.m. to 12 p.m. CT
Location: Poster Section 49, Poster Board Number: 13
Journal: Clinical Cancer Research

CAR binders affect CAR T cell tonic signaling, durability, and sensitivity to target

Session: PO.IM01.01 – CAR-T Cells
Time: 9 a.m. to 12 p.m. CT
Location: Poster Section 37, Poster Board Number: 9
Journal: Cancer Immunology Research

Clinical implications of The Cancer Genome Atlas molecular classification system in esophagogastric cancer

Session: PO.MCB08.03 – Genomic Profiling of Tumors 1
Time: 2-5 p.m. CT
Location: Poster Section 11, Poster Board Number: 15
Journal: Clinical Cancer Research

---

Wednesday, April 30   

Poster Presentation

Barriers to cancer diagnosis and treatment among women in low- and low-middle-income countries

Session: PO.CL05.02 – Revolutionizing Cancer Care Through Inclusive Clinical Research
Time: 9 a.m. to 12 p.m. CT
Location: Poster Section 30, Poster Board Number: 6
Journal: Cancer Epidemiology, Biomarkers & Prevention